Biogen Inc.: Biogen Announces Topline Results from the Tofer

In the Phase 3 VALOR study, the primary endpoint as measured by the Revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R) did not reach statistical significance; however, signs of reduced

Related Keywords

Cambridge , Cambridgeshire , United Kingdom , United States , American , Timothy Miller , Walter Gilbert , Charles Weissmann , Heinz Schaller , Alfred Sandrock Jr , Ashleigh Koss , Mike Hencke , Kenneth Murray , Head Of Research , Linkedin , Twitter , Ionis Pharmaceuticals Inc , Washington University School Of Medicine , Nasdaq , American Neurological Association , Exchange Commission , Youtube , Facebook , Media Snippet , Washington University School , Alfred Sandrock , Open Label Extension , Slow Vital Capacity , Neurological Association , Annual Meeting Presentation , Ionis Pharmaceuticals , Amyotrophic Lateral Sclerosis , Nobel Prize , Today Biogen , Private Securities Litigation Reform Act , Biogen , Nnounces , Topline , Results , Rom , Ofersen , Hase , Study , Pen , Label , Extension , Sod1 ,